The objectivity of reports describing the use of novel diagnostic tests in the management of ovarian cancer: A critique

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 271-272

  Markman, Maurie ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CHEMOSENSITIVITY; DIAGNOSTIC TEST; EDITORIAL; EVALUATION; HUMAN; MEDICAL LITERATURE; OVARY CARCINOMA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; STANDARDIZATION;

CLINICAL TRIALS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 33846466159     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.11.010     Document Type: Editorial

References (12)

1. Markman M. Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: A call for greater objectivity. Gynecol. Oncol. 102 (2006) 419-420
2. Markman M. The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials. J. Cancer Res. Clin. Oncol. 122 (1996) 573-574
3. Dembo A.J., Davy M., Stenwig A.E., et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. 75 (1990) 263-273
4. Vergote I.B., Kaern J., Abeler V.M., et al. Analysis of prognostic factors in stage I epithelial ovarian carcinoma: Importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse. Am. J. Obstet. Gynecol. 169 (1993) 40-52
5. Crawford S.M., Paul J., Reed N.S., et al. The prognostic significance of the CA-125 nadir in patients that achieve a CA-125 response. J. Clin. Oncol. 23 (2004) 448 [abst 5001]
6. Crawford S.M., and Peace J. Does the nadir CA-125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary. Ann. Oncol. 16 (2006) 47-50
7. Markman M., Liu P.Y., Rothenberg M.L., et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J. Clin. Oncol. 24 (2006) 1454-1458
8. Samson D.J., Seidenfeld J., Ziegler K., et al. Chemotherapy sensitivity and resistance assays: A systemic review. J. Clin. Oncol. 22 (2004) 3618-3630
9. Schrag D., Garewal H.S., Burstein H.J., et al. American Society of Clinical Oncology Technology Assessment: Chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 22 (2004) 3631-3638
10. Veronesi U., Boyle P., Goldhirsch A., et al. Breast cancer. Lancet 365 (2005) 1727-1741
11. Markman M. Use of positron emission tomography scans in ovarian cancer: A diagnostic technique in search of an indication. J. Clin. Oncol. 23 (2005) 7385-7387
12. Simcock B., Neesham D., Quinn M., et al. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol. 103 (2006) 271-276